Ravi Majeti

Ravi Majeti has been instrumental in translating the CD47/SIRPalpha macrophage checkpoint axis into cancer therapy, demonstrating that blocking the CD47 dont-eat-me signal enables macrophage phagocytosis of cancer cells and activates adaptive anti-tumor immunity. His laboratory contributed to the development of magrolimab, the first anti-CD47 antibody to enter late-stage clinical trials. He has identified calreticulin as the pro-phagocytic eat-me signal that must be present for CD47 blockade efficacy. His work has established macrophage phagocytic checkpoints as a new pillar of cancer immunotherapy.